Infinity Pharmaceuticals, Inc.
INFIQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.99K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8,989.00 |
|---|---|
| Enterprise Value | $-8,828,011.00 |
| Earnings per Share | $-0.5 |
| Beta | 8.97 |
| Outstanding Shares | 89,885,492 |
Return
| Return on Equity | 108.35% |
|---|---|
| Return on Assets | -190.90% |
| Return on Invested Capital | -458.62% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -3.16 |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.1 |
| Debt to Equity | -0.24 |
Revenue Sources
No data
Next Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
$1.28 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Infinity Pharmaceuticals Inc.
30 employees
CEO: Adelene Perkins
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-st...